234 related articles for article (PubMed ID: 20812236)
1. Targeting of LcrV virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague.
Do Y; Koh H; Park CG; Dudziak D; Seo P; Mehandru S; Choi JH; Cheong C; Park S; Perlin DS; Powell BS; Steinman RM
Eur J Immunol; 2010 Oct; 40(10):2791-6. PubMed ID: 20812236
[TBL] [Abstract][Full Text] [Related]
2. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
[TBL] [Abstract][Full Text] [Related]
3. Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor.
Do Y; Didierlaurent AM; Ryu S; Koh H; Park CG; Park S; Perlin DS; Powell BS; Steinman RM
Vaccine; 2012 Oct; 30(45):6359-67. PubMed ID: 22947140
[TBL] [Abstract][Full Text] [Related]
4. TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague.
Lin JS; Park S; Adamovicz JJ; Hill J; Bliska JB; Cote CK; Perlin DS; Amemiya K; Smiley ST
Vaccine; 2010 Dec; 29(2):357-62. PubMed ID: 20840834
[TBL] [Abstract][Full Text] [Related]
5. A Recombinant Attenuated
Singh AK; Curtiss R; Sun W
Infect Immun; 2019 Oct; 87(10):. PubMed ID: 31331960
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial Viral Vector-Based and Live Attenuated Vaccines without an Adjuvant to Generate Broader Immune Responses to Effectively Combat Pneumonic Plague.
Kilgore PB; Sha J; Hendrix EK; Motin VL; Chopra AK
mBio; 2021 Dec; 12(6):e0322321. PubMed ID: 34872353
[TBL] [Abstract][Full Text] [Related]
7. Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205/CD205-positive mouse dendritic cells.
Do Y; Park CG; Kang YS; Park SH; Lynch RM; Lee H; Powell BS; Steinman RM
Eur J Immunol; 2008 Jan; 38(1):20-9. PubMed ID: 18081041
[TBL] [Abstract][Full Text] [Related]
8. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
[TBL] [Abstract][Full Text] [Related]
9. Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague.
Bowen W; Batra L; Pulsifer AR; Yolcu ES; Lawrenz MB; Shirwan H
Vaccine; 2019 Sep; 37(38):5708-5716. PubMed ID: 31416643
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in the lcrV gene of Yersinia enterocolitica and their effect on plague protective immunity.
Miller NC; Quenee LE; Elli D; Ciletti NA; Schneewind O
Infect Immun; 2012 Apr; 80(4):1572-82. PubMed ID: 22252870
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine.
Erova TE; Rosenzweig JA; Sha J; Suarez G; Sierra JC; Kirtley ML; van Lier CJ; Telepnev MV; Motin VL; Chopra AK
Clin Vaccine Immunol; 2013 Feb; 20(2):227-38. PubMed ID: 23239803
[TBL] [Abstract][Full Text] [Related]
12. Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.
Wang S; Goguen JD; Li F; Lu S
Vaccine; 2011 Sep; 29(39):6802-9. PubMed ID: 21199697
[TBL] [Abstract][Full Text] [Related]
13. Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine.
Demeure CE; Derbise A; Guillas C; Gerke C; Cauchemez S; Carniel E; Pizarro-Cerdá J
Vaccine; 2019 Jan; 37(1):123-129. PubMed ID: 30467064
[TBL] [Abstract][Full Text] [Related]
14. Yersinia pestis caf1 variants and the limits of plague vaccine protection.
Quenee LE; Cornelius CA; Ciletti NA; Elli D; Schneewind O
Infect Immun; 2008 May; 76(5):2025-36. PubMed ID: 18347051
[TBL] [Abstract][Full Text] [Related]
15. Vaccine Potential of a Recombinant Bivalent Fusion Protein LcrV-HSP70 Against Plague and Yersiniosis.
Gupta A; Narayan B; Kumar S; Verma SK
Front Immunol; 2020; 11():988. PubMed ID: 32595634
[TBL] [Abstract][Full Text] [Related]
16. Yersinia pestis YadC: a novel vaccine candidate against plague.
Murphy BS; Wulff CR; Garvy BA; Straley SC
Adv Exp Med Biol; 2007; 603():400-14. PubMed ID: 17966436
[TBL] [Abstract][Full Text] [Related]
17. Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination.
Derbise A; Hanada Y; Khalifé M; Carniel E; Demeure CE
PLoS Negl Trop Dis; 2015; 9(10):e0004162. PubMed ID: 26473734
[TBL] [Abstract][Full Text] [Related]
18. HSP70 domain II of Mycobacterium tuberculosis modulates immune response and protective potential of F1 and LcrV antigens of Yersinia pestis in a mouse model.
Batra L; Verma SK; Nagar DP; Saxena N; Pathak P; Pant SC; Tuteja U
PLoS Negl Trop Dis; 2014 Dec; 8(12):e3322. PubMed ID: 25474358
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV.
DeBord KL; Anderson DM; Marketon MM; Overheim KA; DePaolo RW; Ciletti NA; Jabri B; Schneewind O
Infect Immun; 2006 Aug; 74(8):4910-4. PubMed ID: 16861680
[TBL] [Abstract][Full Text] [Related]
20. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity.
Eyles JE; Butcher WA; Titball RW; Hill J
Vaccine; 2007 Oct; 25(42):7301-6. PubMed ID: 17869388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]